Aug 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S.
Novo NordiskNVO said Thursday it will pay up to $5.2 billion to acquire Akero TherapeuticsAKRO for its experimental liver disease treatment. Akero stock catapulted 16.3%, closing at 54.08, while Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback